ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
1 story in the last 7 days
The latest weight loss news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks weight loss across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

Pharmaceutical companies are developing oral GLP-1 drugs as alternatives to injections. Two teams published Phase II trial data this month on candidates aleniglipron and elecoglipron, showing weight loss comparable to existing options. Eli Lilly's oral pill Foundayo (ofolifeigron) was approved in April, while Astrazeneca advances elecoglipron.
Summaries by ByteBrief